This week, the US Food and Drug Administration (FDA) has authorised the provisional use of the Pfizer COVID-19 vaccine in children between the age of 5 to 11 years. Children will receive two doses of the vaccine, at a reduced dose (one-third of the adult dose) administered approximately three weeks apart.

Pfizer has submitted a partial application to Australia’s Therapeutic Goods Administration (TGA) and is currently on track to supply the remaining data over the next two weeks. Once approved, the Australian Technical Advisory Group on Immunisations (ATAGI) will advise the government on timing the rollout.

Current data suggests a clear advantage to immunising children against COVID-19, including protecting them from severe complications associated with the Delta variant, and helping to minimise the spread of the virus amongst the more vulnerable in the community.

Follow this link to read the full article:

COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far